Results 211 to 220 of about 154,329 (309)

Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome. [PDF]

open access: yesCommun Med (Lond)
Mehravar S   +7 more
europepmc   +1 more source

Distinct Brain Drivers and Shared Cerebello–Cortical Input in ADCY5 and SGCE Hyperkinetic Movements

open access: yesMovement Disorders, EarlyView.
Resting‐state fMRI and effective connectivity revealed distinct cerebellar–basal ganglia–cortical interactions in ADCY5 (MxMD‐ADCY5) and SGCE (MYC/DYT‐SGCE) related movement disorders. The cerebellum modulated cortex directly in MYC/DYT‐SGCE, but indirectly via basal ganglia‐cerebellar projections in MxMD‐ADCY5, which also showed reduced subthalamic ...
Clément Tarrano   +33 more
wiley   +1 more source

Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7‐Year Prospective Matched Cohort Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Although clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear.
Li Zhou   +17 more
wiley   +1 more source

On the relationships between apathy, depression and anhedonia. [PDF]

open access: yesJ Neurol Neurosurg Psychiatry
Zhao S   +15 more
europepmc   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman   +5 more
wiley   +1 more source

Characterizing treatment initiation with central nervous system-active polypharmacy among adults with dementia. [PDF]

open access: yesAlzheimers Dement
Maust DT   +9 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

open access: yesObesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy